DAVID ABOVIAN: Open Payments
NPI 1326349960 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,389 in 60 payments from 20 companies in 2025. Trend: 2023 $581 · 2024 $56 · 2025 $1,389
Food & beverage: $1,294Education: $95
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $248 |
| Incyte Corporation | 7 | $175 |
| Amgen Inc. | 6 | $151 |
| Janssen Biotech, Inc. | 3 | $146 |
| LEO Pharma Inc. | 5 | $119 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Lilly USA, LLC | 3 | $70 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| PFIZER INC. | 2 | $53 |
| Bioventus LLC | 2 | $49 |
Products named: OPZELURA, SKYRIZI, OTEZLA, TREMFYA, DUPIXENT, ADBRY, RINVOQ, TALTZ.
Industry payments across CA — which companies pay providers there.
